A story we follow
Moderna and Merck Personalized mRNA Melanoma Vaccine Meets Phase 3 Endpoints
Tracks the INTerpath-001 phase 3 readout of individualized intismeran autogene plus pembrolizumab after melanoma resection, including how commentators describe the method, mix earlier follow-up figures with the new readout, and treat mRNA as a general cancer platform.
A story page follows one specific event across podcast discussions, with an overview and a timeline of what changed. It updates when new episodes discuss the event, and you can get those updates by email or push. How our formats work
By email or push, when we publish an update to this story. It does not subscribe you to other stories.
Overview
Moderna and Merck announced on 19 August 2026 interim Phase 3 INTerpath-001 results. Individualized intismeran autogene plus pembrolizumab improved recurrence-free and distant-metastasis-free survival over pembrolizumab alone in 1,137 patients with resected stage IIB to IV melanoma. Overall survival is still being evaluated, and the companies describe the therapy as investigational, with regulatory submissions planned.
On the 29 August 2026 Moonshots episode, Peter Diamandis called it the first Phase 3 validation of personalized mRNA immunotherapy. He quoted 49 and 59 percent reductions that belong to earlier five-year Phase 2b follow-up, not to published Phase 3 effect sizes. He also reported a roughly 110 percent stock jump. Dave Blundon said the result was widely anticipated inside the company, and Alex called mRNA a general platform.
In the Moonshots Live panel published 29 September 2026, an unlabeled questioner raised Moderna's record one-day stock gain, which no source checks. Cathie Wood said the move makes sense if the result is what ARK thinks it is, a vaccine against cancer. Her wording that the therapy "seems to be approved" should not be read as an approval, since the companies describe a positive trial result for an experimental therapy. She called healthcare the most undervalued space in the AI theme, with major winners and losers to come. In her view, markets miss it because healthcare analysts distrust moving fast and tech analysts avoid regulated, reimbursement-bound healthcare.
Recent coverage
Changes to our coverage published in the past seven days. These are site update dates; podcast discussion dates and sources are in each version.
No changes to this account were published in the past seven days.
What changed
Dates show when each podcast discussion was published.
-
Interpretation
On 29 September 2026, Cathie Wood was asked about Moderna's record one-day stock gain. She said it makes sense if the result is a cancer vaccine, as ARK believes. She called healthcare the most undervalued part of the AI theme, and said healthcare and tech analysts rarely cross over. This is her interpretation; her wording on approval does not match the companies' account of a positive trial result for an experimental therapy.
-
New information
Moonshots discussed Moderna and Merck's personalized mRNA melanoma vaccine as the first successful phase 3 of its kind. Peter mixed five-year phase 2 percentages with the new readout. Alex called lipid-nanoparticle mRNA a general platform. Dave said the result was widely anticipated inside the company.
Podcast discussions
- Moonshots with Peter Diamandis Cathie Wood on Tesla-SpaceX Merger, $1M Bitcoin, More AIs Than Humans | EP #296 | Moonshots LiveSep 29, 2026
- Moonshots with Peter Diamandis OpenAI Pauses Frontier Training, Elon's 100X Prediction Lands, Robot Beats Usain Bolt with Emad Mostaque | EP#282Aug 29, 2026
Sources
- 01
- 02
- 03
Our coverage
Merck and Moderna say personalized melanoma vaccine met phase 3 goals
Merck and Moderna said personalized mRNA therapy intismeran autogene plus Keytruda beat Keytruda alone on melanoma recurrence-free and distant-metastasis-free survival in a 1,137-patient phase 3 interim analysis. No effect sizes were released.
Version history
-
Oct 1, 2026 · Version 2
On 29 September 2026, Cathie Wood was asked about Moderna's record one-day stock gain. She said it makes sense if the result is a cancer vaccine, as ARK believes. She called healthcare the most undervalued part of the AI theme, and said healthcare and tech analysts rarely cross over. This is her interpretation; her wording on approval does not match the companies' account of a positive trial result for an experimental therapy.